FeesSafety
Pluang+

IG Group gains broker support despite mixed views on revenue growth and trading returns.

Market News
23 Oct 2026
Proactive Investors
View Source
Bullish
IG Group gains broker support despite mixed views on revenue growth and trading returns.

IG Group Holdings Plc received positive backing from brokers Panmure Liberum and Peel Hunt after its capital markets day, with both recommending the shares but differing on growth outlooks. Panmure Liberum is bullish with a 'buy' rating and a 1,500p price target, highlighting customer growth and cross-selling potential as key drivers. Peel Hunt is more cautious, maintaining an 'add' rating and a 1,150p target, citing concerns over trading returns and margin improvements. Both agree on the strength of IG's customer strategy but differ on how quickly revenue and margins will grow.

IG Group's broker outlooks provide context for readers following financial markets. For readers following Financials-sector US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 18:02 WIB: of 142 priced stocks, 50 rose and 84 fell. Notable movers include SMFG at USD 23.65 with a -1.83% change and a typical hold time of 8 days, Blackstone Inc at USD 116.61 with a -1.80% change and 55% sell order activity, and BBVA at USD 24.59 with a -1.76% change and 100% buy order activity. The most notable figure is BBVA's 100% buy order activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
17 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App